Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatinib treatment

Pediatr Blood Cancer. 2022 Aug;69(8):e29714. doi: 10.1002/pbc.29714. Epub 2022 Apr 20.

Abstract

Although skin complications are common adverse events from tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML), no reports have focused on skin and soft tissue infections (SSTIs) associated with TKI use. We herein present five episodes of SSTIs in three CML patients under dasatinib treatment. All patients were adolescents and had been receiving dasatinib for more than 4 years. In contrast, none of 41 adult CML patients experienced SSTIs in a retrospective analysis. Our findings suggest that long-term dasatinib treatment in adolescent patients may be associated with the increased risk of SSTIs.

Keywords: adolescent; cellulitis; chronic myeloid leukemia; dasatinib; skin and soft tissue infections; tyrosine kinase inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Dasatinib / adverse effects
  • Humans
  • Imatinib Mesylate / adverse effects
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Protein Kinase Inhibitors / adverse effects
  • Pyrimidines / adverse effects
  • Retrospective Studies
  • Soft Tissue Infections* / chemically induced

Substances

  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Dasatinib